

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A cell line which synthesizes and expresses on the cell surface Thomsen-Friedenreich antigen (TF), mucin 1 (MUC1), and glycoporphin, wherein the TF is exposed.
2. (Cancelled)
3. (Currently amended) The cell line of claim 1 which is selected from the group consisting of
 - (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and
 - (c) subclones of (a) or (b) which synthesizes and express on the cell surface TF, MUC1, and glycoporphin, wherein the TF is exposed.
4. (Cancelled)
5. (Previously presented) The cell line of claim 1, comprising a vector which comprises a nucleic acid molecule.
6. (Original) The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory

molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual hormone, adjuvant, antibody or other molecules or fragments thereof having biological activity or any combination thereof.

7-10. (Cancelled)

11. (Currently amended) A composition comprising a cell line which synthesizes and expresses on the cell surface TF, MUC1, and glycoporphin, wherein the TF is exposed.

12. (Previously presented) The composition of claim 11, which is a pharmaceutical or vaccine composition.

13-22. (Cancelled)

23. (Previously presented) The cell line of claim 1, wherein the glycoporphin is asialoglycoporphin.

24. (Previously presented) The cell line of claim 1, wherein the MUC1 is tumor-associated MUC1 (TA-MUC1).

25. (New) The cell line of claim 1, wherein the cell line is obtainable from a TF-negative cell line that endogenously or recombinantly expresses MUC1 and GPA.

26. (New) The cell line of claim 1, wherein the cell line is obtainable from an immortalized cell line.

27. (New) The cell line of claim 26, wherein the immortalized cell line expresses the BCR-ABL fusion gene.

28. (New) The cell line of claim 1, wherein the cell line is obtainable from the K562 cell line.
29. (New) The cell line of claim 1, wherein the cell line is obtainable by chemical mutagenesis.
30. (New) The cell line of claim 29, wherein the chemical mutagen is ethyl methanesulfonate (EMS).